MICS does not degrade optical quality of cornea

Article

Microincision cataract surgery (MICS) does not degrade the optical quality of the cornea, however, it does introduce changes in coma and higher order aberrations, according to a Spanish study.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
Planet Earth, made up of pixels, on orange and blue futuristic background. Some of the pixels are flying into space to represent data being transmitted globally. Image credit: ©vit_mar – stock.adobe.com

Crafting an international database for retinopathy of prematurity

Hattie Hayes;Caroline Catt, MB, BS, FRANZCO
February 5th 2025
Article

Intercontinental collaboration is key to unlocking ROP in our lifetime

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A person in a suit sits at a laptop. A US Food and Drug Administration logo and approval badge are superimposed over the image. Image credit: ©Nirusmee – stock.adobe.com

US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema

Martin David Harp
February 4th 2025
Article

Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States

A man wearing Nuance Audio hearing aid glasses speaks to a friend. Image courtesy of EssilorLuxottica

Nuance Audio hearing aid glasses receive concurrent CE Mark and FDA approval

Emily Kaiser Maharjan
February 4th 2025
Article

The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA

An illustrated eyeball inside a DNA helix. Image credit: ©Adisak – stock.adobe.com

Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy

Grace Koennecke
February 3rd 2025
Article

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

A gloved hand holding a syringe, superimposed over the European Union flag. Image credit: ©Savvapanf Photo – stock.adobe.com

European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars

Hattie Hayes
February 3rd 2025
Article

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

© 2025 MJH Life Sciences

All rights reserved.